Your browser doesn't support javascript.
loading
A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial.
Hayer, Manvir K; Edwards, Nicola C; Slinn, Gemma; Moody, William E; Steeds, Rick P; Ferro, Charles J; Price, Anna M; Andujar, Cecilio; Dutton, Mary; Webster, Rachel; Webb, David J; Semple, Scott; MacIntyre, Iain; Melville, Vanessa; Wilkinson, Ian B; Hiemstra, Thomas F; Wheeler, David C; Herrey, Anna; Grant, Margaret; Mehta, Samir; Ives, Natalie; Townend, Jonathan N.
Afiliação
  • Hayer MK; Birmingham Cardio-Renal Group (University of Birmingham Institute of Cardiovascular Sciences), Queen Elizabeth Hospital, Edgbaston, Birmingham.
  • Edwards NC; Birmingham Cardio-Renal Group (University of Birmingham Institute of Cardiovascular Sciences), Queen Elizabeth Hospital, Edgbaston, Birmingham.
  • Slinn G; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham.
  • Moody WE; Birmingham Cardio-Renal Group (University of Birmingham Institute of Cardiovascular Sciences), Queen Elizabeth Hospital, Edgbaston, Birmingham.
  • Steeds RP; Birmingham Cardio-Renal Group (University of Birmingham Institute of Cardiovascular Sciences), Queen Elizabeth Hospital, Edgbaston, Birmingham.
  • Ferro CJ; Birmingham Cardio-Renal Group (University of Birmingham Institute of Cardiovascular Sciences), Queen Elizabeth Hospital, Edgbaston, Birmingham.
  • Price AM; Birmingham Cardio-Renal Group (University of Birmingham Institute of Cardiovascular Sciences), Queen Elizabeth Hospital, Edgbaston, Birmingham.
  • Andujar C; Birmingham Cardio-Renal Group (University of Birmingham Institute of Cardiovascular Sciences), Queen Elizabeth Hospital, Edgbaston, Birmingham.
  • Dutton M; Birmingham Cardio-Renal Group (University of Birmingham Institute of Cardiovascular Sciences), Queen Elizabeth Hospital, Edgbaston, Birmingham.
  • Webster R; Birmingham Cardio-Renal Group (University of Birmingham Institute of Cardiovascular Sciences), Queen Elizabeth Hospital, Edgbaston, Birmingham.
  • Webb DJ; Edinburgh Hypertension Excellence Centre and Clinical Research Centre, BHF Centre of Research Excellence, University of Edinburgh, 47 Little France Crescent, Edinburgh, Scotland, United Kingdom.
  • Semple S; Edinburgh Hypertension Excellence Centre and Clinical Research Centre, BHF Centre of Research Excellence, University of Edinburgh, 47 Little France Crescent, Edinburgh, Scotland, United Kingdom.
  • MacIntyre I; Edinburgh Hypertension Excellence Centre and Clinical Research Centre, BHF Centre of Research Excellence, University of Edinburgh, 47 Little France Crescent, Edinburgh, Scotland, United Kingdom.
  • Melville V; Edinburgh Hypertension Excellence Centre and Clinical Research Centre, BHF Centre of Research Excellence, University of Edinburgh, 47 Little France Crescent, Edinburgh, Scotland, United Kingdom.
  • Wilkinson IB; Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, and Cambridge Clinical Trials Unit, Cambridge University Hospitals, PO Box 98, Addenbrooke's Hospital, Cambridge.
  • Hiemstra TF; Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, and Cambridge Clinical Trials Unit, Cambridge University Hospitals, PO Box 98, Addenbrooke's Hospital, Cambridge.
  • Wheeler DC; Department of Renal Medicine, Royal Free Hospital, Pond St, London.
  • Herrey A; Department of Renal Medicine, Royal Free Hospital, Pond St, London.
  • Grant M; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham.
  • Mehta S; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham.
  • Ives N; Birmingham Clinical Trials Unit, Institute of Applied Health Research, University of Birmingham, Birmingham.
  • Townend JN; Birmingham Cardio-Renal Group (University of Birmingham Institute of Cardiovascular Sciences), Queen Elizabeth Hospital, Edgbaston, Birmingham. Electronic address: john.townend@uhb.nhs.uk.
Am Heart J ; 191: 37-46, 2017 Sep.
Article em En | MEDLINE | ID: mdl-28888268
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Espironolactona / Clortalidona / Hipertrofia Ventricular Esquerda / Ventrículos do Coração / Falência Renal Crônica Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Am Heart J Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Espironolactona / Clortalidona / Hipertrofia Ventricular Esquerda / Ventrículos do Coração / Falência Renal Crônica Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Am Heart J Ano de publicação: 2017 Tipo de documento: Article